Afficher la notice abrégée

One-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort

dc.rights.licenseopenen_US
dc.contributor.authorLOUBET, Paul
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorNINOVE, Laetitia
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorCHALOUNI, Mathieu
dc.contributor.authorBARROU, Benoit
dc.contributor.authorBLAY, Jean-Yves
dc.contributor.authorHOURMANT, Maryvonne
dc.contributor.authorTHOUVENOT, Eric
dc.contributor.authorLAVILLE, Martine
dc.contributor.authorLAVIOLLE, Bruno
dc.contributor.authorLELIEVRE, Jean-Daniel
dc.contributor.authorMOREL, Jacques
dc.contributor.authorNGUYEN QUOC, Stephanie
dc.contributor.authorSPANO, Jean-Philippe
dc.contributor.authorTERRIER, Benjamin
dc.contributor.authorTHIEBAUT, Anne
dc.contributor.authorVIALLARD, Jean-Francois
dc.contributor.authorVRTOVSNIK, Francois
dc.contributor.authorCIRCOSTA, Sophie
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorESTERLE, Laure
dc.contributor.authorLEVIER, Axel
dc.contributor.authorVANHEMS, Philippe
dc.contributor.authorTARTOUR, Eric
dc.contributor.authorPARFAIT, Beatrice
dc.contributor.authorDE LAMBALLERIE, Xavier
dc.contributor.authorLAUNAY, Odile
dc.date.accessioned2023-03-13T10:55:30Z
dc.date.available2023-03-13T10:55:30Z
dc.date.issued2023-03-01
dc.identifier.issn1198-743Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/172271
dc.description.abstractEnObjectives : We aimed to investigate the 1-month humoral response to two or three doses of a messenger RNA coronavirus disease 2019 (COVID-19) vaccine as a primary vaccination regimen in specific populations compared with that in healthy adults. Methods : Agence Nationale Recherche contre le Sida (ANRS)0001S–COV-POPART (NCT04824651) is a French nation-wide, multi-centre, prospective, observational cohort study assessing the immune response to COVID-19 vaccines routinely administered to 11 sub-groups of patients with chronic conditions and two control groups. Patients and controls who received at least two vaccine doses and whose results 1 month after the second dose were available were included. The humoral response was assessed 1 month after the first, second and third doses (if applicable) based on the percentage of responders (positive for anti-Spike severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] IgG antibodies), geometric means of anti-Spike SARS-CoV-2 IgG antibodies (enzyme-linked immunosorbent assay) and proportion of participants with anti-SARS-CoV-2-specific neutralizing antibodies (in vitro neutralization assay for the original SARS-CoV-2 strain). All analyses were centralized. Results : We included 4091 participants in this analysis: 2979 participants from specific sub-populations and 1112 controls. Only 522 (17.5%) participants from the specific populations received three doses as a primary vaccination regimen. Patients living with human immunodeficiency virus, cancer and diabetes had high percentages of responders after two doses, whereas patients with solid organ transplants, allogeneic hematopoietic stem cell transplants and hypogammaglobulinaemia had the lowest percentage of responders (35.9% [95% CI, 29.2–43.0], 57.4% [95% CI, 48.1–66.3] and 77.1% [95% CI, 65.6–86.3], respectively). In those who received the third dose, the percentage of responders reached 54.2% (95% CI, 42.9–65.2) (vs. 32.3% [95% CI, 16.7–51.4] after 2 doses) among those with solid organ transplants and 73.9% (95% CI, 58.9–85.7) (vs. 56.1% [95% CI, 46.2–65.7] after 2 doses) among those with hematopoietic stem cell transplants. Similar results were found with anti-SARS-CoV-2-specific neutralizing antibodies. Conclusions : A lower humoral response to COVID-19 vaccines was observed in the specific populations compared with that in the controls. The third dose of this vaccine in the primary regimen had a positive effect on the percentages of patients who developed anti-Spike IgG antibodies and specific neutralizing antibodies.
dc.language.isoENen_US
dc.subject.enCOVID-19
dc.subject.enEfficacy
dc.subject.enHumoral
dc.subject.enImmunocompromised
dc.subject.enImmunogenicity
dc.subject.enSpecific populations
dc.title.enOne-month humoral response following two or three doses of messenger RNA coronavirus disease 2019 vaccines as primary vaccination in specific populations in France: first results from the Agence Nationale Recherche contre le Sida (ANRS)0001S COV-POPART cohort
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.cmi.2022.10.009en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36252789en_US
bordeaux.journalClinical Microbiology and Infectionen_US
bordeaux.page388.e1-388.e8en_US
bordeaux.volume29en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAgence Nationale de Recherches sur le Sida et les Hépatites Viralesen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Microbiology%20and%20Infection&rft.date=2023-03-01&rft.volume=29&rft.issue=3&rft.spage=388.e1-388.e8&rft.epage=388.e1-388.e8&rft.eissn=1198-743X&rft.issn=1198-743X&rft.au=LOUBET,%20Paul&WITTKOP,%20Linda&NINOVE,%20Laetitia&CHALOUNI,%20Mathieu&BARROU,%20Benoit&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée